Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desvenlafaxine
Drug ID BADD_D00621
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D07793
MeSH ID D000069468
PubChem ID 125017
TTD Drug ID D0O3FG
NDC Product Code 63304-191; 0054-0401; 0054-0603; 14501-0068; 70436-013; 70771-1311; 68382-469; 0054-0400; 70436-036; 70771-1312; 0591-3660; 71335-1815; 68382-105; 46708-152; 70518-3195; 69766-025; 60687-607; 63304-192; 70771-1661; 68382-741; 72888-144; 46708-153; 53002-1801; 71335-1753; 71335-1975; 72888-143; 63629-7524; 70436-012; 0591-3659; 71335-1700; 0591-4060; 50090-4806
UNII NG99554ANW
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C16H25NO2
CAS Registry Number 93413-62-8
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscular weakness17.05.03.005; 15.05.06.001--
Mydriasis17.02.11.003; 06.05.03.0040.001302%Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Narcolepsy17.15.01.002; 19.02.02.0020.000178%Not Available
Nasal congestion22.04.04.0010.001212%
Nausea07.01.07.0010.014941%
Nephrolithiasis20.04.01.0020.000178%
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.0030.003691%Not Available
Night sweats08.01.03.031; 23.02.03.006--Not Available
Nightmare19.02.03.0030.002514%Not Available
Obesity14.03.02.0090.000446%
Oral discomfort07.05.05.0010.000392%Not Available
Orgasm abnormal21.03.02.013; 19.08.01.004--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Osteoarthritis15.01.04.0010.000481%Not Available
Pain in jaw15.02.01.0030.000695%Not Available
Palpitations02.11.04.0120.001961%
Pancreatitis07.18.01.0010.000267%
Pancreatitis acute07.18.01.002--Not Available
Panic attack19.06.04.0010.002318%Not Available
Panic reaction19.06.04.0030.001997%Not Available
Paraesthesia23.03.03.094; 17.02.06.0050.003958%
Paranoia19.05.01.0050.000749%Not Available
Parkinsonism17.01.05.0030.000178%Not Available
Parosmia22.04.03.007; 17.04.04.002--Not Available
Peripheral coldness23.06.04.008; 24.04.03.006; 08.01.09.010--Not Available
Photophobia17.17.02.006; 06.01.01.0040.000784%
Photopsia17.17.01.006; 06.02.06.0040.000606%
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages